Raffa Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $463 | Hold |
23
| – | – | ﹤0.01% | 1204 |
|
|
2026
Q2 | $582 | Hold |
23
| – | – | ﹤0.01% | 1165 |
|
|
2026
Q1 | $512 | Buy |
23
+1
| +5% | +$24 | ﹤0.01% | 1066 |
|
|
2025
Q4 | $588 | Hold |
22
| – | – | ﹤0.01% | 1047 |
|
|
2025
Q3 | $469 | Hold |
22
| – | – | ﹤0.01% | 1082 |
|
|
2025
Q2 | $475 | Hold |
22
| – | – | ﹤0.01% | 1007 |
|
|
2025
Q1 | $365 | Hold |
22
| – | – | ﹤0.01% | 999 |
|
|
2024
Q4 | $404 | Hold |
22
| – | – | ﹤0.01% | 1030 |
|
|
2024
Q3 | $338 | Hold |
22
| – | – | ﹤0.01% | 1021 |
|
|
2024
Q2 | $358 | Hold |
22
| – | – | ﹤0.01% | 1086 |
|
|
2024
Q1 | $407 | Hold |
22
| – | – | ﹤0.01% | 1062 |
|
|
2023
Q4 | $689 | Hold |
22
| – | – | ﹤0.01% | 919 |
|
|
2023
Q3 | $458 | Hold |
22
| – | – | ﹤0.01% | 963 |
|
|
2023
Q2 | $527 | Hold |
22
| – | – | ﹤0.01% | 960 |
|
|
2023
Q1 | $414 | Hold |
22
| – | – | ﹤0.01% | 991 |
|
|
2022
Q4 | $350 | Hold |
22
| – | – | ﹤0.01% | 991 |
|
|
2022
Q3 | $360 | Hold |
22
| – | – | ﹤0.01% | 1090 |
|
|
2022
Q2 | $310 | Hold |
22
| – | – | ﹤0.01% | 1079 |
|
|
2022
Q1 | $533 | Hold |
22
| – | – | ﹤0.01% | 1036 |
|
|
2021
Q4 | $513 | Hold |
22
| – | – | ﹤0.01% | 1043 |
|
|
2021
Q3 | $365 | Hold |
22
| – | – | ﹤0.01% | 1079 |
|
|
2021
Q2 | $537 | Hold |
22
| – | – | ﹤0.01% | 1031 |
|
|
2021
Q1 | $568 | Hold |
22
| – | – | ﹤0.01% | 1022 |
|
|
2020
Q4 | $1.18K | Hold |
22
| – | – | ﹤0.01% | 703 |
|
|
2020
Q3 | $908 | Hold |
22
| – | – | ﹤0.01% | 695 |
|
|
2020
Q2 | $1.07K | Buy |
+22
| New | +$1.06K | ﹤0.01% | 646 |
|
|
2018
Q4 | – | Sell |
-66
| Closed | -$1.37K | – | 742 |
|
|
2018
Q3 | $1.37K | Hold |
66
| – | – | ﹤0.01% | 470 |
|
|
2018
Q2 | $1.01K | Buy |
+66
| New | +$1.18K | ﹤0.01% | 576 |
|
|
2016
Q4 | – | Sell |
-15
| Closed | -$477 | – | 883 |
|
|
2016
Q3 | $477 | Hold |
15
| – | – | ﹤0.01% | 747 |
|
|
2016
Q2 | $487 | Hold |
15
| – | – | ﹤0.01% | 702 |
|
|
2016
Q1 | $419 | Hold |
15
| – | – | ﹤0.01% | 745 |
|
|
2015
Q4 | $535 | Hold |
15
| – | – | ﹤0.01% | 665 |
|
|
2015
Q3 | $496 | Buy |
+15
| New | +$624 | ﹤0.01% | 677 |
|
Other funds holding ACAD
BBA
Raffa Wealth Management's ACAD Position: Q3 2026 in Review
Raffa Wealth Management held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 23 shares worth $463. The position accounts for ﹤0.01% of the portfolio, ranked #1204.
Raffa Wealth Management first reported a position in ACAD in Q3 2015 and has held it in 33 quarters since. The position peaked at $1.37K in Q3 2018. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Raffa Wealth Management held 23 shares of Acadia Pharmaceuticals worth $463 as of Q3 2026.
- Raffa Wealth Management left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
- Acadia Pharmaceuticals made up ﹤0.01% of Raffa Wealth Management's portfolio in Q3 2026, its #1204 holding.
- Raffa Wealth Management first reported a position in Acadia Pharmaceuticals in Q3 2015 and has held it in 33 quarters since.
- Raffa Wealth Management's Acadia Pharmaceuticals position peaked at $1.37K in Q3 2018.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Raffa Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.